Pasithea Therapeutics (KTTA) EBITDA (2021 - 2026)

Pasithea Therapeutics' EBITDA history runs 6 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

• In Q1 2026, EBITDA rose 20.26% year-over-year to -$2.8 million; the TTM figure through Mar 2026 stood at -$19.7 million (down 44.62% YoY), while the FY2025 annual figure was -$20.4 million, down 46.75% from the prior year.
• EBITDA came in at -$2.8 million for Q1 2026 at Pasithea Therapeutics, up from -$10.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.6 million in Q1 2022 to a low of -$10.1 million in Q4 2025.
• A 5-year average of -$3.9 million and a median of -$3.6 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 897.6% in 2022 and surged 37.57% in 2024, its largest moves.
• Pasithea Therapeutics' EBITDA stood at -$5.0 million in 2022, then declined by 1.47% to -$5.0 million in 2023, then soared by 37.57% to -$3.1 million in 2024, then tumbled by 221.01% to -$10.1 million in 2025, then surged by 71.9% to -$2.8 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.8 million, -$10.1 million, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison